Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma

Current Treatment Options in Oncology

Volumn 7, Issue 4, 2006, Pages 276-284

  Friedberg, Jonathan W ^a   Freedman, Arnold S ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; CD20 ANTIBODY; CPG OLIGODEOXYNUCLEOTIDE; EPRATUZUMAB; GALIXIMAB; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 2; MONOCLONAL ANTIBODY; RECOMBINANT ALPHA INTERFERON; RITUXIMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CELL MEDIATED CYTOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOSTIMULATION; INFECTION; INJECTION SITE REACTION; LOW DRUG DOSE; LYMPHOCYTOSIS; NONHODGKIN LYMPHOMA; NONHUMAN; OPTIMAL DRUG DOSE; REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, NON-HODGKIN;

EID: 33745914936     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-006-0037-2     Document Type: Review

References (39)

1. Nadler LM, Stashenko P, Hardy R, et al.: Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980, 40:3147-3154.
2. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
3. Ghielmini M, Schmitz SF, Cogliatti SB, et al.: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 2004, 103:4416-4423
4. Ghielmini M: Multimodality therapies and optimal schedule of antibodies: rituximab in lymphoma as an example. Hematology (Am Soc Hematol Educ Program) 2005, 321-328.
5. Gordon LI, Solal-Celigny P, Gascoyne RD, Freedman AS: Follicular lymphoma: management options in the era of targeted therapy. In ASCO Educational Book. 2005:511-526.
6. Friedberg JW: Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology (Am Soc Hematol Educ Program) 2005, 329-334.
7. Smith MR: Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003, 22:7359-7368.
8. Uchida J, Hamaguchi Y, Oliver JA, et al.: The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004, 199:1659-1669.
9. Cartron G, Dacheux L, Salles G, et al.: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754-758.
10. Ghielmini M, Rufibach K, Salles G, et al.: Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005, 16:1675-1682.
11. Weng WK, Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003, 21:3940-3947.
12. Fisher RI, Dana BW, LeBlanc M, et al.: Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol 2000, 18:2010-2016.
13. Cheson BD: The curious case of the baffling biological. J Clin Oncol 2000, 18:2007-2009.
14. Davis TA, Maloney DG, Grillo-Lopez AJ, et al.: Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res 2000, 6:2644-2652.
15. Sacchi S, Federico M, Vitolo U, et al.: Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 2001, 86:951-958.
16. Malik UR, Makower DF, Wadler S: Interferon-mediated fatigue. Cancer 2001, 92(Suppl):1664-1668.
17. Friedberg JW, Neuberg D, Gribben JG, et al.: Combination immunotherapy with rituximab and interleukin-2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 2002, 117:1-7.
18. Gluck WL, Hurst D, Yuen A, et al.: Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004, 10:2253-2264.
19. Ansell SM, Witzig TE, Kurtin PJ, et al.: Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 2002, 99:67-74.
20. Liu NS, Grimm EA, Poindexter NJ, et al.: Rituximab, alone and in combination, for treatment of patients with indolent B cell lymphoma. Am J Oncol Rev 2005, 4(Suppl 10):27-33.
21. Kimby E: Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-alpha2a and granulocyte-macrophage colony stimulating factor. Semin Oncol 2002, 29(Suppl 6):7-10.
22. van der Kolk LE, Grillo-Lopez AJ, Baars JW, van Oers MH: Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. Leukemia 2003, 17:1658-1664.
23. Reff ME, Carner K, Chambers KS, et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
24. Golay J, Zaffaroni L, Vaccari T, et al.: Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000, 95:3900-3908.
25. van der Kolk LE, Grillo-Lopez AJ, Baars JW, et al.: Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001, 115:807-811.
26. van der Kolk LE, Evers LM, Omene C, et al.: CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia 2002, 16:1735-1744.
27. Jazirehi AR, Bonavida B: Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005, 24:2121-2143.
28. Coleman M, Goldenberg DM, Siegel AB, et al.: Epratuzumab: targeting B-cell malignancies through CD22. Clin Cancer Res 2003, 9:3991S-3994S.
29. Friedberg JW: Developing new monoclonal antibodies for aggressive lymphoma: a challenging road in the rituximab era. Clin Cancer Res 2004, 10:5297-5298.
30. Leonard J, Coleman M, Matthews J, et al.: High complete response rate following epratuzumab (anti-CD22) and rituximab (anti-CD20) combination antibody therapy in follicular non-Hodgkin's lymphoma. Ann Oncol 2002, 13(Suppl 2):38.
31. Emmanouilides C, Leonard JP, Schuster SJ, et al.: Multicenter, phase 2 study of combination antibody therapy with epratuzumab plus rituximab in recurring low-grade NHL. Blood 2003, 102:69a.
32. Friedberg JW, Leonard JP, Younes A, et al.: Updated results from a phase II study of galiximab (anti-CD80) in combination with rituximab for relapsed or refractory follicular NHL. Blood 2005, 106:685a.
33. Klinman DM: Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004, 4:249-258.
34. Kawarada Y, Ganss R, Garbi N, et al.: NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 2001, 167:5247-5253.
35. Weiner GJ, Liu HM, Wooldridge JE, et al.: Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A 1997, 94:10833-10837.
36. Vicari AP, Chiodoni C, Vaure C, et al.: Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002, 196:541-549.
37. Jahrsdorfer B, Hartmann G, Racila E, et al.: CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2001, 69:81-88.
38. Friedberg JW, Kim H, McCauley M, et al.: Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005, 105:489-495.
39. Friedberg JW, Kelly J, Kutock JL, et al.: CpG oligonucleotide (1018 ISS) may overcome rituximab resistance in follicular lymphoma through enhanced ADCC, T cell expansion, and alteration of tumor microenvironment. Blood 2005, 106:684a.